Hatice Eylül BOZKURT YILMAZ, Mustafa YILMAZ, Füsun ÖNER EYÜPOĞLU

Akut pulmoner tromboembolizmin tanı ve takibinde plazma asimetrik dimetilarjin düzeylerinin rolü

Amaç: Nitrik oksit trombosit yapışması ve toplanmasında rol oynayan önemli bir maddedir. Asimetrik dimetilarjinin (ADMA) endotelyal nitrik oksit sentetazın yarışmacı inhibitörüdür ve seviyesi hipokside artar. Bu çalışmada ADMA seviyesin akut pulmoner tromboembolizm tanı ve takibindeki yerini araştırmayı amaçladık.Gereç ve Yöntem: Çalışma prospektif olarak dizayn edildi. Akut pulmoner tromboembolizmi olan 30 hasta ve 20 sağlıklı gönüllü çalışmaya dahil edildi. Hastalar 1 ay takip edildi. Plazma ADMA seviyesi başvuruda ve 1. ay takipte ölçüldü.Bulgular: Hastaneye başvuru sırasındaki hasta ve kontrol grubunun serum ADMA seviyeleri arasında istatistiksel anlamlı fark vardı. Birinci ay kontrolde rezolüsyonu olan ve olmayan grupların serum ADMA değişimi arasında istatistiksel anlamlı fark bulunmadı. Serum ADMA seviyesi masif olan grupta, submasif ve masif olmayan gruplara göre daha yüksekti. Sonuç: Plazma ADMA seviyesi akut pulmoner tromboembolizmi olan hastalarda yükselir ve ADMA seviyesi trombüs yükü ile koreledir.

Anahtar Kelimeler:

Pulmoner emboli, asimetrik dimetilarjinin, nitrik oksit

Role of plasma asymmetric dimethylarginine levels in diagnosis and follow-up of acute pulmonary thromboembolism

Purpose: Nitric oxide is an important mediator that plays a major role in platelet adhesion/aggregation. Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of endothelial nitric oxide synthase. In this study, we aimed to examine the ADMA levels in diagnosis and follow-up of acute pulmonary thromboembolism.Materials and Methods: The study was designed as a prospective study. Thirty consecutive patients with acute PTE and 20 healthy volunteers were enrolled into the study. Patients were followed 1 month. Plasma ADMA levels were measured on admission and following the first month.Results: Ona dmision there was statistically significant difference between two groups. When we compared serum ADMA levels difference between patients group with resolution and without resolution, there was not any statistically significant difference. There was a significant difference between serum ADMA levels of massive group and the other 2 groups.Conclusion: Plasma ADMA levels elevated in patients with pulmonary thromboembolism. This finding supports the idea ADMA levels correlated with thrombus burden.

Keywords:

Pulmonary embolism, asymmetric dimethylarginine, nitric oxide,

PDF

___

1. Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med. 2010;363:266-74.
2. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35:3033-69.
3. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28:370–2.
4. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756-64.
5. Girard P, Sanchez O, Leroyer C, Musset D, Meyer G, Stern JB et al. Deep venous thrombosis in patients with acute pulmonary embolism: prevalence, risk factors, and clinical significance. Chest. 2005;128:1593-600.
6. Riedel M. Acute pulmonary embolism 1: Pathophysiology, clinical presentation, and diagnosis. Heart. 2001;85:229-40.
7. Furchgott RF, The Discovery of endothelium derived relaxing factor and its importance in the identification of nitric oxide. J Am Med Assn. 1996;276:1186-8.
8. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000;102:994-9.
9. Sydow K, Munzel T. ADMA and oxidative stress. Atherosclerosis suppl. 2003;4:41-51.
10. Skoro-Sajer N, Mittermayer F, Panzenboeck A, Bonderman D, Sadushi R, Hitsch R et al. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2007;176:1154-60.
11. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-7.
12. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet. 1992;339:572-5.
13. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethyl argininein humans. Circulation. 2004;109:172-7.
14. Milat LJ, Whitley J, Leiper JM, Jeimes LD, Siragy MH, Carey RM et al. Evidence for Dysregulation of Dimethyl arginine Dimethyl aminohydrolase I in Chronic Hypoxia induced Pulmonary Hypertension. Circulation. 2003;108:1493-98.
15. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:21-9.
16. James E. Dalen. Pulmonary embolism: What have we learned since Virchow? natural history, pathophysiology, and diagnosis. Chest. 2002;122:1440-56.
17. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:14-8.
18. Bulau P, Zakrzewicz D, Kitowska K, Leiper J, Gunther A, Grimminger F et al. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol. 2006;292:18-24.
19. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation. 2003;107:1195–201.
20. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J. 2005;19:1175-7.
21. Sasaki A, Doi S, Mizutani S, Azuma H. Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol. 2007;292:1480-7.
22. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O’Hara B et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13:198-203.
23. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol. 2001;37:489-92.
24. Haider DG, Bucek RA, Reiter M, Minar E, Hron G, Kyrle PA et al. The cardiovascular risk marker asymmetrical dimethylarginine is not affected by venous thromboembolism. Transl Res. 2006;148:26-9.
25. Altuntaş M, Atalay F, Can M, Altın R, Tor M. Serum asymmetric dimethylarginine, nitrate, vitamin B(12), and homocysteine levels in individuals with pulmonary embolism. Mediators Inflamm. 2011;2011:215057.